Annual report pursuant to Section 13 and 15(d)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.8.0.1
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Net loss $ (4,897,139) $ (14,141,298)
Cash flows from operations 3,615,004 (2,053,740)
Impairment of intangible assets 0 2,746,512
Restricted cash 778,579 275,611
Cash in excess of FDIC limits 1,547,408  
Allowance for doubtful accounts 200,000 100,000
Shipping and handling 854,436 497,227
Shipping and handling charged to customers 230,213 101,515
Allowance for customer returns 0 0
Inventory 8,489,686 9,330,499
Inventory write-down 0 3,562,459
Depreciation expense 147,395 195,167
Research and development 724,329 1,159,009
Advertising expense 380,284 311,217
Germany and The Netherlands [Member]    
Inventory 680,516 680,516
Consumer Products [Member]    
Impairment of intangible assets   2,746,512
Inventory write-down   3,562,459
Research and development 251,134 834,963
Specialty Pharmaceuticals [Member]    
Impairment of intangible assets   0
Inventory write-down   0
Research and development $ 473,195 $ 324,046
Accounts Receivable [Member] | One Customer [Member]    
Concentration risk percentage   58.00%
Options [Member]    
Antidilutive shares 23,073,277 15,591,000
Warrants [Member]    
Antidilutive shares 2,850,000 2,100,000
Common Stock [Member] | Performance-Based Stock Options [Member]    
Antidilutive shares 18,000,000